Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Nature Communications

Volumn 11, Issue 1, 2020, Pages

  Sheahan, Timothy P ^a   Sims, Amy C ^a   Leist, Sarah R ^a   Schäfer, Alexandra ^a   Won, John ^a   Brown, Ariane J ^a   Montgomery, Stephanie A ^b   Hogg, Alison ^c   Babusis, Darius ^c   Clarke, Michael O ^c   Spahn, Jamie E ^c   Bauer, Laura ^c   Sellers, Scott ^c   Porter, Danielle ^c   Feng, Joy Y ^c   Cihlar, Tomas ^c   Jordan, Robert ^c   Denison, Mark R ^d   Baric, Ralph S ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GILEAD SCIENCES   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CASPASE 3; DIPEPTIDYL PEPTIDASE IV; LOPINAVIR PLUS RITONAVIR; PRODRUG; REMDESIVIR; ADENOSINE PHOSPHATE; ALANINE; ANTIVIRUS AGENT; CARBOXYLESTERASE; CES1C PROTEIN, MOUSE; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR;

ANTIMICROBIAL ACTIVITY; COMPARATIVE STUDY; INFECTIVITY; PATHOLOGY; RESPIRATORY DISEASE; VIRUS;

ACUTE LUNG INJURY; AIRWAY RESISTANCE; AMERICAN THORACIC SOCIETY LUNG INJURY SCORE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BODY PLETHYSMOGRAPHY; BRONCHOCONSTRICTION; CALU-3 CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DEBRIDEMENT; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GAS EXCHANGE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG FUNCTION; LUNG INJURY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY; MOUSE; NONHUMAN; PEAK EXPIRATORY FLOW; PROPHYLAXIS; PROTEIN EXPRESSION; SCORING SYSTEM; THERAPEUTIC EQUIVALENT DOSE; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CORONAVIRUS INFECTION; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; KNOCKOUT MOUSE; PATHOLOGY;

SAUDI ARABIA;

CORONAVIRUS; MUS;

ADENOSINE MONOPHOSPHATE; ALANINE; ANIMALS; ANTIVIRAL AGENTS; CARBOXYLESTERASE; CORONAVIRUS INFECTIONS; DRUG COMBINATIONS; DRUG DEVELOPMENT; FEMALE; HUMANS; INTERFERON-BETA; LOPINAVIR; LUNG INJURY; MALE; MICE; MICE, KNOCKOUT; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RITONAVIR; VIRAL LOAD; VIRUS REPLICATION;

EID: 85077715855     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-13940-6     Document Type: Article

References (56)

1. de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).
2. Muller, M. A. et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect. Dis. 15, 629 (2015).
3. Dudas, G., Carvalho, L. M., Rambaut, A. & Bedford, T. MERS-CoV spillover at the camel-human interface. eLife 7, e31257 (2018).
4. Morra, M. E. et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev. Med Virol. 28, e1977 (2018).
5. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/ (2018).
6. Cho, S. Y. et al. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. Lancet 388, 994–1001 (2016).
7. Kaletra. Highlights of Prescribing Information. https://www.rxabbvie.com/pdf/kaletratabpi.pdf (2017).
8. Chan, J. F. et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67, 606–616 (2013).
9. de Wilde, A. H. et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875–4884 (2014).
10. Hart, B. J. et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 95, 571–577 (2014).
11. Chan, J. F. et al. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212, 1904–1913 (2015).
12. Kim, U. J., Won, E. J., Kee, S. J., Jung, S. I. & Jang, H. C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. Antivir. Ther. 21, 455–459 (2016).
13. Spanakis, N. et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J. Antimicrob. Agents 44, 528–532 (2014).
14. Arabi, Y. M. et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19, 81 (2018).
15. Arabi, Y. M. Twitter account for MIRACLE Trial. (2019).
16. Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 7, 43395 (2017).
17. Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).
18. Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381–385 (2016).
19. Jordan, P. C. et al. Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathog. 14, e1006889 (2018).
20. Tchesnokov, E. P., Feng, J. Y., Porter, D. P. & Gotte, M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11, 326 (2019).
21. Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 169, 104541 (2019).
22. Cockrell, A. S. et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat. Microbiol 2, 16226 (2016).
23. Mo, H. et al. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. J. Viral Hepat. 18, 338–348 (2011).
24. Douglas, M. G., Kocher, J. F., Scobey, T., Baric, R. S. & Cockrell, A. S. Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease. Virology 517, 98–107 (2018).
25. Fukushi, M. et al. Serial histopathological examination of the lungs of mice infected with influenza A virus PR8 strain. PLoS ONE 6, e21207 (2011).
26. Matute-Bello, G. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 44, 725–738 (2011).
27. Arabi, Y. M. MERS-CoV infection treated with a combination of lopinavir/ritonavir and interferon beta-1b (MIRACLE). https://clinicaltrials.gov/ct2/show/NCT02845843 (2016).
28. Menachery, V. D., Gralinski, L. E., Baric, R. S. & Ferris, M. T. New metrics for evaluating viral respiratory pathogenesis. PLoS ONE 10, e0131451 (2015).
29. Schmidt, M. E. et al. Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. PLoS Pathog. 14, e1006810 (2018).
30. Lossi, L., Castagna, C. & Merighi, A. Caspase-3 mediated cell death in the normal development of the mammalian cerebellum. Int. J. Mol. Sci. 19, 3999 (2018).
31. Ge, X. Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).
32. Woo, P. C. et al. Molecular diversity of coronaviruses in bats. Virology 351, 180–187 (2006).
33. Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S. & Yuen, K. Y. Coronaviruses—drug discovery and therapeutic options. Nat. Rev. Drug Disco. 15, 327–347 (2016).
34. Lambert, J. S. et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 12, 166–173 (2011).
35. Friedman, R. M. Clinical uses of interferons. Br. J. Clin. Pharm. 65, 158–162 (2008).
36. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258–267 (1957).
37. Falzarano, D. et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19, 1313–1317 (2013).
38. Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl Acad. Sci. USA 111, 4970–4975 (2014).
39. Channappanavar, R. et al. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J. Infect. Dis. 212, 1894–1903 (2015).
40. Li, K. et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J. Infect. Dis. 213, 712–722 (2016).
41. Falzarano, D. et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 10, e1004250 (2014).
42. Johnson, R. F. et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology 485, 422–430 (2015).
43. Davidson, S. et al. IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. EMBO Mol. Med. 8, 1099–1112 (2016).
44. Galani, I. E. et al. Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity 46, 875–890 e876 (2017).
45. Kim, S. et al. The Superiority of IFN-lambda as a therapeutic candidate to control acute influenza viral lung infection. Am. J. Respir. Cell Mol. Biol. 56, 202–212 (2017).
46. Aeffner, F., Bolon, B. & Davis, I. C. Mouse models of acute respiratory distress syndrome: a review of analytical approaches, pathologic features, and common measurements. Toxicol. Pathol. 43, 1074–1092 (2015).
47. National Institute of Allergy and Infectious Diseases (NIAID). Center, N.I.o.H.C. Investigational Therapeutics for the Treatment of People With Ebola Virus Disease NCT03719586. https://clinicaltrials.gov/ct2/show/NCT03719586?term=NCT03719586&draw=2&rank=1 (2019).
48. National Institute of Allergy and Infectious Diseases (NIAID). Center, N.I.o.H.C. GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen NCT02818582. https://clinicaltrials.gov/ct2/show/NCT02818582?term=NCT02818582&draw=2&rank=1 (2019).
49. Choi, W. S. et al. Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea. Infect. Chemother. 48, 118–126 (2016).
50. Oh, M. D. et al. Viral load kinetics of MERS coronavirus infection. N. Engl. J. Med. 375, 1303–1305 (2016).
51. de Wit, E. et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antivir. Res. 156, 64–71 (2018).
52. Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9, e00221-18(2018).
53. Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 110, 16157–16162 (2013).
54. Betaseron. Highlights of Prescribing Information. https://labeling.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf (2015).
55. Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27–31 (2016).
56. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408 (2001).